References
- Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, et al.CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro Oncol 2013;15 Suppl 2:ii1–56.
- Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al.The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97–109.
- Claus EB, Walsh KM, Wiencke JK, Molinaro AM, Wiemels JL, Schildkraut JM, et al. Survival and low-grade glioma: the emergence of genetic information. Neurosurg Focus 2015;38:E6.
- Hervey-Jumper SL, Li J, Lau D, Molinaro AM, Perry DW, Meng L, et al. Awake craniotomy to maximize glioma resection: methods and technical nuances over a 27-year period. J Neurosurg 2015;1–15.
- Santagata S, Eberlin LS, Norton I, Calligaris D, Feldman DR, Ide JL, et al. Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery. Proc Natl Acad Sci U S A 2014;111:11121–11126.
- Roessler K, Becherer A, Donat M, Cejna M, Zachenhofer I. Intraoperative tissue fluorescence using 5-aminolevolinic acid (5-ALA) is more sensitive than contrast MRI or amino acid positron emission tomography ((18)F-FET PET) in glioblastoma surgery. Neurol Res 2012;34:314–317.
- Olubiyi OI, Ozdemir A, Incerkera F, Dolati P, Tie Y, Hsu L, et al. Intra-operative magnetic resonance imaging in intracranial glioma resection: a single center retrospective blinded volumetric study. World Neurosurg, 2015.
- Mert A, Kiesel B, Wohrer A, Martinez-Moreno M, Minchev G, Furtner J, et al. Introduction of a standardized multimodality image protocol for navigation-guided surgery of suspected low-grade gliomas. Neurosurg Focus 38:E4.
- Suzuki H, Aoki K, Chiba K, Sato Y, Shiozawa Y, Shiraishi Y, et al. Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 2015;47:458–468.
- Kanamori M, Kikuchi A, Watanabe M, Shibahara I, Saito R, Yamashita Y, et al. Rapid and sensitive intraoperative detection of mutations in the isocitrate dehydrogenase 1 and 2 genes during surgery for glioma. J Neurosurg 2014;120:1288–1297.
- Suzuki S, Komori M, Hirai M, Ureshino N, Kimura S. Development of a novel, fully-automated genotyping system: principle and applications. Sensors (Basel) 2012;12:166141-166127.
- Takahashi H, Mizuta T, Oeda S, Isoda H, Nakashita S, Kawaguchi Y, et al. An automated rapid detection system using the quenching probe method for detecting interleukin 28B and inosine triphosphatase single nucleotide polymorphisms in chronic hepatitis C. J Viral Hepat 2013;20:e124–e126.
- Wakita S, Yamaguchi H, Miyake K, Mitamura Y, Kosaka F, Dan K, et al. Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia. Leukemia 2011;25:1423–32.
- Kato Y, Natsume A, Kaneko MK. A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation. Biochem Biophys Res Commun 2013;432: 564–567.
- Chen R, Ravindra VM, Cohen AL, Jensen RL, Salzman KL, Prescot AP, et al. Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas. Neurosurg Focus 2015;38:E2.
- Cohen AL, Colman H. Glioma biology and molecular markers. Cancer Treat Res 2015;163:15–30.
- Sipayya V, Sharma I, Sharma KC, Singh A. Immunohistochemical expression of IDH1 in gliomas: a tissue microarray-based approach. J Cancer Res Ther 2012;8:598–601.
- Nitta M, Muragaki Y, Maruyama T, Ikuta S, Komori T, Maebayashi K, et al. Proposed therapeutic strategy for adult low-grade glioma based on aggressive tumor resection. Neurosurg Focus 2015;38:E7.
- Beiko J, Suki D, Hess KR, Fox BD, Cheung V, Cabral M, et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol 2014;16:81–91.
- Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 2008;26: 1338–1345.